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INTRODUCTION:  Administration  of  ineffective  anticancer  therapy  is associated  with  unnecessary  toxic-
ity and  development  of  resistant  clones.  Cancer  stem  cells  (CSCs)  resist  chemotherapy,  thereby  causing
relapse  of  the  disease.  Thus,  development  of a test  that  identiﬁes  the  most  effective  chemotherapy  man-
agement  offers  great  promise  for  individualized  anticancer  treatments.  We  have  developed  an  ex  vivo
chemotherapy  drug  response  assay  (ChemoID®), which  measures  the  sensitivity  of CSCs  as well  as  the
bulk  of  tumor  cells  to a variety  of chemotherapy  agents  to  assist  an  oncologist  in making  treatment
decisions.
METHODS:  Three  patients  affected  by oral  cancer  were referred.
RESULTS:  Biopsy  showed  a well-differentiated  squamous  cell carcinoma  (G1)  in  case  1, a  G2 adenocarci-
noma  in case  2 and  a  G3 squamous  cell  carcinoma  in case  3. In all of  the  three  cases, after clinical  inspection
and  suspicion  of a  diagnosis  of  cancer,  a double  biopsy  was  performed.  One  specimen  was  sent  to  the
ChemoID  laboratory  for chemosensitivity  assay  and  the  other  for  histological  analysis.  Chemotherapy
dose  response  curves  were  generated,  and  grouped  in  3  categories:  1. No  response  (less  than  30%  cell
kill),  Intermediate  (30–60%  cell kill),  and  3.  Sensitive  (60%  cell kill  or above).
CONCLUSIONS:  This  procedure  may  be  useful  in  helping  physicians  choose  an  effective  chemother-
apy  regimen  for  head  and  neck  cancer  patients  and  lower  treatment  costs  by eliminating  ineffective
chemotherapies  and  unnecessary  toxicity  particularly  in  elderly  patients.
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1. IntroductionBecause of difﬁculties in treatment of head and neck malig-
nant tumors, investigation and development of novel strategies and
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ntegrated therapies are required to ﬁnd more effective treatments
or these malignant tumors [1,2].
Patients with the same stage and grade of cancer may  vary con-
iderably in their clinical response to chemotherapy [3]. Ineffective
nticancer therapy can result in unnecessary toxicity and the devel-
pment of resistant clones. The surviving cancer cells are often
ore resistant to therapy [4]. Many attempts have been made over
he years to develop an ex-vivo anti-cancer test that could help in
iscerning the best treatment options for each individual patient
hile minimizing toxicity [4,5].
Animal xenograft models have shown that only a subset of can-
er cells within each tumor is capable of initiating tumor growth.
his biological behavior, ﬁrst observed in AML, has been extended
o a multitude of solid tumors, including breast, glioblastoma, col-
rectal, ovarian, head & neck, and pancreatic cancers [6–9].
This pool of cancer cells is operationally deﬁned as the “Can-
er Stem Cell” (CSC) subset. According to the “cancer stem cell”
heory, tumors are a complex, growing population of abnormal
ells originating from a minority of CSCs [6–9]. These cells main-
ain stem-like characteristics in that they proliferate very slowly
nd have an inherent capacity to self-renew and differentiate into
henotypically heterogeneous, aberrant progeny [9–11].
Unlike the bulk of tumor cells, CSCs resist chemotherapy and
adiation therapy and are responsible for tumor relapse and metas-
asis [4,6,7,10–14]. Targeting CSCs in addition to the bulk of other
ancer cells within a tumor is a new paradigm in cancer treatment
15].
Our recent studies show that selectively enriched CSCs from pri-
ary cancer cell cultures can be used in a chemosensitivity assay
ChemoID®) [4,11].
ChemoID® is a proprietary drug response assay, which measures
n individual’s malignant tumor response to arrange a standard-of-
are anticancer drugs therapy under consideration by a physician
4,12]. ChemoID® uses one of the most advanced technologies to
dentify chemotherapies that can eliminate the CSCs that are the
oot of the cancer behavior and relapse [4,12]. ChemoID® is a test
hat quantiﬁes an individual cancer patient’s tumor response to var-
ous chemotherapeutic drugs against cancer stem cells and bulk
f tumor cells providing both sensitivity and resistance informa-
ion that can help the Oncologists to tailor the best chemotherapy
ocktail directed against the patient’s cancer cells. This equates
o “individualized” chemotherapy based on the speciﬁc patient’s
wn tumor characteristics to give patients an edge against cancer
4,5,12–15]. ChemoID® can be used for selecting the ﬁrst, second
r third line chemotherapies, whether the aim of chemotherapy is
ure or palliation.
The aim of this study was to demonstrate the feasibility and efﬁ-
acy of the ChemoID® chemo predictive assay, which is performed
n a CLIA accredited laboratory in the United States for patients
ffected by extensive lesions of the oral and maxillofacial area who
re located and treated in Europe, thus opening new prospective
reatment of extensive cancer lesions where a technology such as
hemoID® is not available yet, by just performing two  specimen
iopsies immediately at the beginning of the treatment.
. Material and methods
.1. Chemotherapy agentsBevacizumab (Avastin), Cisplatin, Methotrexate, 5-Fluorouracil,
ocetaxel, Bleomycin, Epirubicin, Gemcitabine, Paclitaxel,
arboplatin, Cetuximab were acquired as clinical grade chemother-
py agents.PEN  ACCESS
rgery Case Reports 26 (2016) 42–46 43
2.2. Methods for collecting biopsy specimen from oral cavity and
shipping modalities
We have developed a specimen collection procedure that
involves a thorough disinfection of the oral cavity before the biopsy,
followed by a subsequent disinfection of the collected specimen
with a Betadine solution, followed by a wash of the specimen with a
sterile saline solution before placing in the transportation medium.
Fresh biopsy specimens were shipped using courier services in
a specially designed temperature controlled styrofoam container
packaging. Biopsy specimens were received at the ChemoID labo-
ratory in the United States within 18–36 h from Europe.
Samples were transported in sterile test tubes containing
RPMI-1640 culture media with 2% Penicillin/Streptomycin. The
professionally designed cardboard packaging followed interna-
tional standards for impact durability and safety for the shipment
of biological materials.
For international shipments, a lead sheet of 2.5 mm thickness
was wrapped around the biopsy collection vial to shield from radia-
tion exposure of airport x-ray scanners. The radiation shielding lead
sheet ensured biopsy viability for recovering optimum live cells for
the assay.
Another innovative aspect of the collection process that we
developed is the implementation of a methodical aseptic procedure
at the time of biopsy collection, particularly for oral cancers. Biopsy
specimens taken from the oral cavity are usually very high in bac-
terial and fungal content even after several chlorhexidine rinses.
To minimize contamination problems, we  developed a decontam-
ination procedure that consists of thorough disinfection of the oral
cavity prior to the biopsy, followed by a subsequent disinfection
of the specimen with a Betadine solution. This was followed by a
meticulous wash of the specimen with a sterile saline solution to
remove the Betadine disinfectant.
2.3. Patients
The study was conducted in accordance with the ethical prin-
ciples provided by the Declaration of Helsinki and the principles
of good clinical practice, under the IRB protocol number 695141.
Case 1 was  a 55 years old woman, heavy smoker, obese, without
any history for other pathology, who consulted our the Department
of Medicine and Surgery, Unit of Maxillofacial Surgery, University
of Salerno, Salerno, Italy for a neoplastic ulcer of the left buccal
mucosa of about 6 cm in diameter, inﬁltrating the muscles of the
cheek. Clinical examination revealed pain in the involved area.
The patient didn’t suffer from human immunodeﬁciency virus
(HIV-1) infection. She did not complain of bleeding, and no other
signiﬁcant complaints were present in her clinical history. On Com-
puterized Tomography (CT) exam there was  clear presence of the
tumor and other suspicious lymph nodes at the level of the sub-
mandibular and hyoid bone in the absence of distant metastases,
with a staging of T4, N2, M0,  and a G1 grade carcinoma at the
pathological exam.
Case 2 was  an 83 years old woman  with an adenocarcinoma (G2)
of the left submandibular gland with mandibular bone involvement
and spontaneous bleeding, and without distant metastases who
was staged as T4 N2 M0.
Case 3 was  a 53 years old man  with a recurrent lower lip
carcinoma and submandibular lymph nodes involvement. He was
operated for the ﬁrst time in Bulgaria for tumor resection without
laterocervical neck dissection. Some months later he was operated
in Italy two more times for recurrence of the tumor and then
he was  referred to our Department where he was staged as an
inoperable T4 N2 M0  because of carotid inﬁltration at CT scan
 –  OPEN  ACCESS
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Fig. 1. Clinical presentation and CT scans of case a recurrent lower lip carcinomaCASE  REPORT
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maging. A biopsy was performed resulting in the diagnosis of a
3 squamous cell carcinoma.
.4. ChemoID® assay
The ChemoID® assay is a second-generation functional drug
esponse assay that targets cancer stem cells and bulk of tumor
ells. It is a clinical laboratory-developed test, which is performed in
 CLIA certiﬁed and CAP accredited clinical laboratory at the Cabell
untington Hospital and Edwards Cancer Center in West Virginia,
SA.
Sensitivity to chemotherapy was assessed using a viability assay
MTT) on both CSCs and bulk of tumor cells plated in 5 replicas
nto 96-well plates. Brieﬂy, equal number of bulk of tumor cells
nd CSCs, were grown, counted and seeded separately in 96-well
ishes and incubated at 37 ◦C for 24-h as previously described [4].
The cells were then challenged for a 1-h pulse with a panel of
nticancer drugs as chosen by the oncologist to mimic  the aver-
ge clinical chemotherapy infusion schedule. All anticancer drugs
ere each tested in a range of doses including the clinically relevant
ose. An MTT  assay was performed 48-h following chemotherapy
reatment to assess cell viability as previously described [4]. A dose
esponse chart was developed in which samples were scored as
esponsive (0–30% cell survival), intermediate (30–60% cell sur-
ival), and non-responsive (60–100% cell survival).
. Results
For the ﬁrst case (Table 1) the ChemoID® assay indicated that the
SC and bulk of tumor cells of this patient were sensitive to Pacli-
axel and Carboplatin (70% and 85% cell kill, respectively), but not to
ther chemotherapies tested such as Cisplatin, 5-Fluorouracil, Doc-
taxel, Bleomycin, Epirubicin, Methotrexate and Cetuximab (less
han 10%). Patient was operated with a resection of the tumor and
 neck dissection, followed by reconstruction using a forehead ﬂap.
In the second case ChemoID® assay indicated that the CSC
nd bulk of tumor cells of this patient were sensitive to Epiru-
icin (60% cell kill), but not to the other chemotherapies tested
uch as Methotrexate, Cisplatin, combination of Cetuximab and
arboplatin, 5-Fluorouracil, Carboplatin, Paclitaxel and Docetaxel
between 30 and 10%). Unfortunately both patients 1 and 2 refused
oth radiation and chemotherapy treatment options and were lost
t follow-up.
For the third case the ChemoID® assay indicated that the CSC
nd bulk of tumor cells of this patient were sensitive to Cisplatin
nd a combination of Cisplatin and 5-Fluorouracil (70% and 50%
ell kill, respectively), but not to the other chemotherapies tested
uch as 5-Fluorouracil, Carboplatin, Methotrexate, Paclitaxel and
ocetaxel (between 30 and 10%). Patient #3 was not a surgical
andidate because of a massive inﬁltration of the carotid artery
y the tumor. Patient was treated by chemotherapy according to
he ChemoID® assay results and a good outcome was  recorded at
 months with signiﬁcant tumor reduction measured by CT scan
Fig. 1).
. Discussion
The ChemoID® drug sensitivity assay used in this study, mea-
ures the survival of CSCs and bulk of tumor cells cultured from
uman cancer biopsies following chemotherapy [4]. The ChemoID®
rug sensitivity assay has been tested and it is currently used to
easure sensitivity of cancer stem cells to different chemother-
pies in several solid malignancies including lung, breast, brain,
olon, ovarian carcinoma, and advanced prostate, renal and pan-
reatic carcinoma, and metastatic melanoma.
inﬁltrating the submandibular area. (A) Patient view showing a large relapse of a
lower lip carcinoma inﬁltrating the submandibular area. (B) CT scan of the head and
neck showing a large inﬁltrating mass in the submandibular area. (C) 6 months
follow-up CT scan of the head and neck post chemotherapy according to the
ChemoID assay showing signiﬁcant tumor reduction.
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Table  1
Data is reported as percentage of cell kill. Chemotherapies are indicated as: Responsive if 60%–100% cell kill is observed. Intermediate Response if 30%–60% cell kill is observed.
Non-responsive if <10%–30% cell kill is observed.
Patient 1 Patient 2 Patient 3
Responsive 60%-100%
Cell Kill
Paclitaxel 80 mg/m2  (70%) Epirubicin 100 mg/m2
(60%)
Cisplatin 100 mg/m2 (70%)
Carboplatin 70 mg/m2  (85%) Cisplatin
60 mg/m2 + 5-Fluorouracil
800 mg/m2 (50%)
Intermediate response 30%-60% Cell Kill
Non-Responsive < 10%–30% Cell Kill Cisplatin 60 mg/m2  (20%) Methotrexate 40 mg/m2 (15%) Methotrexate 40 mg/m2  (15%)
5-Fluorouracil 1000 mg/m2  (15%) Cisplatin 100 mg/m2  (<10%) 5-Fluorouracil 1000 mg/m2 (<10%)
Docetaxel 70 mg/m2 (<10%) Cetuximab
250 mg/m2 + Carboplatin
100 mg/m2  (<10%)
Carboplatin 25 mg/m2  (<10%)
Bleomycin 15 mg/m2  (<10%) 5-Fluorouracil 500 mg/m2 (<10%) Paclitaxel 80 mg/m2  (<10%)
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Methotrexate 40 mg/m2 (<10%)
Cetuximab 400 mg/m2 (<10%) 
The advantage of the ChemoID® assay is to aid the oncologists
n selecting the most appropriate chemotherapy regimen on an
ndividual basis especially when a number of equivalent options
re available [4,15–18]. The ChemoID® assay allows various avail-
ble chemotherapy drugs, which are part of standard-of-care to be
ested, for efﬁcacy against the cancer stem cells as well as the bulk
f tumor cells [4].
The ChemoID® assay reports are usually released within 21 days
rom the acceptance of a viable biopsy at the ChemoID lab, there-
ore we obtained two biopsies. One specimen was  submitted to
ur local Department of Pathology for histological diagnosis and
ne specimen was shipped to the ChemoID lab for chemother-
py sensitivity assessment. In this way the treating physician can
eceive the result of the drug response assay against the individ-
al cancer stem cells and bulk of tumor cells prior to initiating
hemotherapy. ChemoID assay can be particularly useful to help
uide chemotherapy selection both in cases of post surgical can-
er relapse and in non-surgically operable tumors because of poor
ealth conditions of the patient [19]. In those cases of post-surgical
arge tumor recurrence in which the patient cannot be subjected
o a second surgery for poor health conditions or for the inﬁltra-
ion and extension of the tumor to vital structures, the utility of a
hemoID® assay to avoid resistant drugs is even more compelling
20]. In fact this is particularly important because this new diag-
ostic test may  decrease unnecessary toxicity for patients already
roven and with a bad performance status derived by ineffective
hemotherapies. The effectiveness of this procedure also dwells in
ts safety because the same biopsy procedure can be used to obtain
he second specimen for ChemoID purposes at the time in which
 biopsy is performed for histological diagnosis without causing
dditional stress to the patient.
Hypothesis of future prospective use of the ChemoID assay could
e the treatment of extensive cancer lesions of the maxillofacial
rea combining surgery and speciﬁc chemotherapy against CSCs.
The ChemoID assay has the additional advantage that it can be
epeated after a few cycles of chemotherapy if needed, because
t has been previously demonstrated [4] that chemotherapy may
ecome ineffective following some cycles of its administration due
o the selection of resistant clones in the CSC populations [14]. In
hese cases the ChemoID assay could be used to further analyze the
ensitivity of the CSCs from a relapsed tumor against a larger panel
f drugs.
Unfortunately, in some of the very advanced cases, the use of
he ChemoID assay may  not be indicated because patients cannot
ait 21 days before initiating therapy, however this test could be
ore useful if performed as a routine examination at earlier stages
n case of the need to replace the surgical therapeutic step with
hemotherapy [21].Carboplatin 100 mg/m2  (<10%) Docetaxel 70 mg/m2 (<10%)
Paclitaxel 175 mg/m2 (<10%)
Docetaxel 75 mg/m2 (<10%)
Although generally chemotherapy is not widely used in head
and neck tumors, the use of this novel drug response assay, could
increase the adoption of chemotherapy to treat this type of cancer
as an alternative therapeutic step in those cases in which surgery
or radiation are not an option.
The present communication is the ﬁrst report of a successful
technique to ensure the shipment of viable live biological samples
from Europe to the United States, which allowed cancer cells and
cancer stem cells to be cultured and the ChemoID test to be per-
formed. In our small cohort of patients affected by head & neck
cancer we  tested, unfortunately patients 1 and 2 refused radiation
and/or chemotherapy treatment options and were lost at follow-
up. However patient 3 affected by an advanced cancer of the oral
pavement inﬁltrating the surrounding tissues and vital organs was
successfully treated, thereby providing further evidence that per-
sonalized therapy can be useful for the management of therapy
refractory and inoperable head & neck cancers.
5. Conclusions
ChemoID® results from these three cases of head and neck
cancer we  conducted showed the technical feasibility of this labo-
ratory procedure even for patients hospitalized in other countries
at transcontinental distances from the ChemoID lab. Larger stud-
ies using head and neck tumors will be needed to gain more
objective data about drugs effectiveness on various head and neck
tumors in order to avoid useless toxicity for patients and high costs
for the health care system. The selective and speciﬁc analysis for
chemosensitivity offered by a test such as the ChemoID® assay
will be useful for the development of new therapies and for testing
new chemotherapy drugs in clinical management of head and neck
cancer.
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